ImmuCell (NASDAQ:ICCC) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

ImmuCell Corporation (NASDAQ:ICCC) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.12 and traded as high as $6.72. ImmuCell shares last traded at $6.56, with a volume of 10,233 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell presently has an average rating of “Sell”.

ImmuCell Stock Performance

The stock has a fifty day moving average price of $5.80 and a 200 day moving average price of $6.12. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27. The firm has a market cap of $56.63 million, a price-to-earnings ratio of 24.08 and a beta of 0.18.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%. The company had revenue of $5.51 million for the quarter.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently bought a new position in ImmuCell stock. Steadtrust LLC bought a new stake in shares of ImmuCell Corporation (NASDAQ:ICCC) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned 0.35% of ImmuCell as of its most recent SEC filing. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.